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adiposity of the individual, we hypothesized that this effect could be due
to the modulation of inﬁltrating T cells by the tissue-resident adipocytes.
Therefore, we investigated whether adipocytes from IFP can modulate
CD4+ T cell cytokine production.
Methods: CD4+ T cells were puriﬁed from peripheral blood mononuclear
cells isolated from buffycoats obtained from healthy volunteers. The
purity of the CD4+ T cells isolated using magnetic beads coated with
anti-human CD4 was above 95%. Plate-bound anti-CD3 and soluble anti-
CD28 antibodies were used to activate T cells. Adipocytes were isolated
from IFP of OA patients by collagenase digestion and were either cultured
with puriﬁed CD4+ T cells or were cultured in vitro for 24 hours in
DMEM/F12 medium supplemented with 0.5% bovine serum albumin
to generate adipocyte-conditioned medium (ACM). Cytokine production
was measured by intracellular cytokine staining (ICS), ELISA or cytokine
multiplex. Separation of the protein and lipid fractions was performed
using the Bligh and Dyer method, followed by precipitation of the protein
fraction and reconstitution in culture medium.
Results: CD4+ T cells produced increase levels of IFNg when activated
in the presence of adipocytes. This effect is mediated by soluble
mediators, as shown in transwell and ACM transfer experiments.
Moreover, separation of the protein and lipid fractions from the ACM
medium showed that soluble factors present in the protein fraction can
mediate this effect. Measurement of ten different cytokines known to
be secreted by T cells upon activation revealed that, besides IFNg, also
TNFa, IL-17 and IL-5 are modulated by IFP-derived ACM.
Conclusions: Soluble mediators secreted by IFP of OA patients can
modulate cytokine production of CD4+ T cells. Although the precise
mechanism involved in this modulation is still unknown, protein/lipid
fractionation studies indicated that molecules present in the protein
fraction can mediate this effect.
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TENASCIN-C LEVELS IN SYNOVIAL FLUID ARE ELEVATED AFTER
HUMAN JOINT INJURY AND CORRELATE WITH MARKERS OF MATRIX
DEGRADATION AND INFLAMMATION
P.S. Chockalingam1, W. Sun1, S. Lohmander2,3. 1Inﬂammation &
Remodelling, Pﬁzer, Cambridge, MA, USA; 2Lund Univ., Lund, Sweden; 3Univ.
of Southern Denmark, Odense, Denmark
Purpose: Tenascin-C (TNC) is a modular, multifunctional extracellular
matrix glycoprotein associated with the development of articular
cartilage that decreases during maturation of chondrocytes, and almost
disappears in adult cartilage. It is highly reexpressed in the cartilage and
synovium of diseased joints [1], and stimulates the production of pro-
inﬂammatory cytokines in human macrophages and synovial ﬁbroblasts
through activation of Toll-like receptor-4 (TLR4) [2]. We have shown
elevated levels of TNC in joint ﬂuid in animal models of joint disease [3],
and shown the capacity of TNC to induce inﬂammatory mediators and
matrix degradation in vitro in human joint cartilage [4]. The objective
of this study was to determine the release of TNC into synovial ﬂuid of
patients in joint disease and after joint injury, and to correlate levels of
TNC with markers of cartilage matrix degradation and inﬂammation in
the same ﬂuids.
Methods: Human knee synovial ﬂuids (n = 160) were obtained without
lavage from a cross-sectional convenience cohort. Diagnosis was
by arthroscopy, radiography, assessment of joint ﬂuid and clinical
examination. Diagnostic groups were knee healthy reference (REF
n=8), anterior cruciate ligament rupture, with or without concomitant
meniscus lesions (ACL n=56), isolated meniscus injury (MI n =69), acute
inﬂammatory arthritis (AIA n=16) and osteoarthritis (OA n=11). TNC
was measured using TNC Large ELISA (IBL®), with anti-TN-C 19C4MS mab
against the FNIII-C domain for capture, and HRP conjugated anti-TN-C
4F10TT mouse mab against the EGF domain for detection. ARG-aggrecan,
MMP1 and MMP3 ELISAs were performed as described [5,6].
Results: TNC in synovial ﬂuids varied widely between 44 and 2430ng/ml
(Table). Signiﬁcantly higher levels of TNC compared to REF subjects were
observed in all disease groups: 7, 5, 10, and 4-fold higher in ACL, MI, AIA,
and OA, respectively. TNC levels of ACL and MI patients decreased over
time following joint injury. Synovial ﬂuid levels of TNC were signiﬁcantly
correlated with aggrecanase-dependent ARG-aggrecan fragment release
(r = 0.46) and MMP1 (r = 0.51) and MMP3 protein (r = 0.46).
Conclusions: We show strongly elevated levels of TNC in human knee
joints immediately after injury or onset of disease, associated with
markers of inﬂammation and matrix degradation. Due to the complex
function of TNC we can only speculate on the consequences of the
increased TNC release into joint ﬂuid on cartilage matrix function and
disease development. TNC has a role in the assembly of the chondrocyte
matrix and as a soluble mediator of chondrocytes; deﬁciency of TNC
delays articular cartilage repair in mice [7]. The induction by TNC of TLR4,
inﬂammatory pathways, and matrix degradation in articular cartilage is
consistent with the correlation observed in the current study between
TNC levels and ARG-aggrecan fragments, MMP1, and MMP3 in human
synovial ﬂuids. TNC may serve as a marker of joint tissue injury.
ACL MI
Study Group 0–12w 12–52w >52w 0–12w 12–52w >52w AIA OA REF
Mean
sampling
time w
(range)
1 (0–6) 25 (13–48) 279
(57–1115)
3 (0–12) 24 (13–40) 418
(52–1926)
32 (0–510) 189
(0–481)
-
N 26 8 22 27 22 20 16 11 8
Mean age
(range)
25 (14–50) 31 (17–50) 31 (14–53) 34
(18–59)
35 (16–55) 45
(28–70)
68 (30–91) 67
(39–86)
28
(17–42)
Mean
OA grade
(range)
1 (1–3) 2 (1–3) 3 (1–6) 2 (0–5) 2 (0–3) 3 (1–8) 3 (0–9) 8 (3–9) 1 (0–1)
% male 62 63 68 93 86 70 63 45 75
Mean TCN
(ng/ml)
(range)
631
(196–1888)
533
(215–1032)
339
(101–1405)
405
(96–903)
327
(47–1062)
284
(12–1170)
939
(196–2430)
354
(107–817)
91
(44–218)
TNC 95% CI 459, 803 327, 739 212, 466 323, 487 207, 447 165, 402 587, 1290 236, 472 50, 132
Mean fold
/REF
6.9 5.9 3.7 4.5 3.6 3.1 10.3 3.9 -
p-value 0.0009 0.0005 0.0156 0.0001 0.0152 0.0298 0.0016 0.0011 -
Reference(s)
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“ALARMINS” S100A8 AND A9 ARE EXPRESSED IN THE SYNOVIUM
OF EARLY OA PATIENTS AND ARE INVOLVED IN DRIVING SYNOVIAL
ACTIVATION AND JOINT DESTRUCTION DURING EXPERIMENTAL
OSTEOARTHRITIS
P. van Lent. Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands
Purpose: “alarmins” S100 A8 and A9 are prominent proteins released
by activated phagocytes Evidence is accumulating that synovial tissue
activation contributes to OA cartilage pathology The aim was to evaluate
the presence of S100A8/S100A9 in synovia of patients with early OA
and to explore active involvement of S100A8/A9 in cartilage destruction
in experimental osteoarthritis models that differ in degree of synovial
activation.
Methods: Arthroscopic biopsies were taken from 30 early OA patients.
mRNA levels (RT-PCR) and immunolocalisation was determined and
related to joint destruction (Kellgren Lawrence score). Experimental OA
was either induced by transsection of the medial anterior meniscotibial
ligament which leads to destabilisation of the medial meniscus (DMM)
or by injection of collagenase into murine knee joints, which causes
overall ligament damage and broad instability. Collagenase-induced-
osteoarthritis involves chronic synovial activation in contrast to DMM.
Synovial expression of S100A8 and S100A9 was measured using
immunolocalisation. Both models were induced in S100A9−/− deﬁcient
mice (myeloid cells also lack S100A8 at the protein level). Primary
chondrocytes were stimulated with S100A8 and A9 and MMP levels
were measured using RT-PCR.
Results: mRNA and protein levels of S100A8 and A9 were signiﬁcantly
higher in synovial biopsies of early OA patients when compared to control
joints. S100 was predominantly found in synovial macrophages. Of great
interest, high levels correlated to increased joint destruction (KL score).
The function of S100A8 and S100A9 was further studied in experimental
OA models. Kinetic studies show that in surgically induced DMM model,
S100A8 and A9 was marginally expressed within the synovium, only
evident at day 7 after induction and consistent with limited synovial
thickening. The degree of OA cartilage pathology was similar in S100A9−/−
and WT mice at day 42 after induction of DMM.
In contrast, during the course of collagenase-induced osteoarthritis,
S100A8 and S100A9 was strongly upregulated in synovium at day 7
and remained high at days 14, 28 and 42. Expression of these proteins
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nicely correlated with thickening of the synovial lining layer comprising
activated macrophages. When collagenase-induced-osteoarthritis was
elicited in S100A9−/− mice, signiﬁcantly lower synovial activation was
observed when compared to WT mice. Synovial activation was 62% lower
at day 42. Cartilage destruction was signiﬁcantly lower in all surfaces
and ranged from a 45% reduction in the lateral tibia to 73% reduction in
the medial femur. When primary mouse chondrocytes were stimulated
with S100A8 or S100A9, a strong upregulation of particularly MMP-3
mRNA level was found indicating a direct role of S100A8/A9 in cartilage
destruction.
Conclusions: Alarmins S100A8/S100A9 are expressed by phagocytes in
biopsies of early OA patients. S100A8/A9 play a crucial role in synovial
activation and cartilage destruction in an osteoarthritis model that shows
clear synovial involvement. S100A8/A9 expression in the synovium
causes pathology probably by stimulating MMP-mediated damage in
the cartilage matrix.
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ONCOSTATIN M POTENTLY INDUCES IL-6 AND RANKL EXPRESSION
IN MOUSE SYNOVIAL FIBROBLASTS AND SIGNIFICANTLY ENHANCES
THE EFFECTS OF IL-1 AND TNF
B. Le Goff1, B.A. Tonkin1, S. Singbrant1, T.J. Martin1,2, E. Romas1,2,
N.A. Sims1,2, N.C. Walsh1,2. 1St Vincent’s Inst. of Med. Res., Melbourne,
Australia; 2Dept. of Med., St Vincent’s Hosp., Univ. of Melbourne, Melbourne,
Australia
Purpose: Oncostatin M (OSM) is a multipotent cytokine that is expressed
in synovium from rheumatoid arthritis (RA) and osteoarthritis (OA)
patients. OSM alone, or in concert with pro-inﬂammatory cytokines
such as IL-1 or TNF, can stimulate synovial ﬁbroblasts (SFs) to express
genes that promote inﬂammation and joint destruction in arthritis. This
study determined the acute effects of OSM, IL-1, and TNF and their
combination on expression of IL-6 and RANKL in SFs.
Methods: SFs were isolated from non-arthritic mice deﬁcient in OSM
receptor expression (OSMR−/−) and strain-matched wildtype control
mice (OSMR+/+). SFs were stimulated with mouse OSM (2ng/mL), mouse
IL-1 (10ng/mL) or mouse TNF (7.5 ng/mL) and their combination for 1,
6 and 24 hrs. Gene expression was assessed by quantitative RT-PCR
analyses. Flow cytometry and immunohistochemistry were performed
to identify protein expression.
Results: In OSMR+/+ SFs, OSM and IL-1 increased IL-6 mRNA expression
by 80 fold at 6 hrs, with OSM further increasing expression at 24 hrs
(135 fold vs. 40-fold, IL-1). TNF treatment resulted in a small transient
increase in IL-6 mRNA expression which peaked at 1 hr (9 fold) and
returned to baseline by 24 hrs. Profound synergistic upregulation of IL-6
mRNA expression was observed when suboptimal doses of OSM and
IL-1 were combined (>1000-fold at 6 and 24 hrs). Combining TNF and
OSM enhanced IL-6 mRNA expression compared to each cytokine alone
at 1 hr (232-fold) but this combination had no additional effect at 6
and 24 hrs compared to OSM alone. OSM, IL-1 and TNF all increased
RANKL mRNA expression at 6 hrs (9 Fold, OSM; 4 Fold, TNF and IL1),
with the effects of TNF and IL-1 returning to baseline by 24 hrs. OSM
treatment, however, further increased RANKL mRNA expression at 24
hrs (20 fold). Combining suboptimal doses of OSM and IL-1 signiﬁcantly
enhanced RANKL expression at 24 hrs (100-fold) but this interaction
was not synergistic. Combining OSM and TNF had no additional effect
on RANKL expression compared to OSM alone. Importantly, OSMR−/− SFs
showed no induction of IL-6 or RANKL mRNA expression in response to
OSM treatment, but did respond to IL-1 and TNF treatment in a similar
manner to the OSMR+/+ SFs. In OSMR+/+ SFs, OSM stimulated mRNA
expression of its co-receptors (OSMR, 6-fold at 6 and 24 hrs, and gp130,
3-fold at 24 hrs). Furthermore, OSM increased IL-1 receptor mRNA and
protein expression at 24 hrs. IL-1 did not regulate its own receptor, but
induced a 3-fold increase in OSMR mRNA expression at 6 and 24 hrs.
OSM had no effect on TNF receptor expression. Finally, immunostaining
demonstrated protein expression of OSM and its co-receptors in the
synovium in normal mouse knee joints; expression was increased in
antigen-induced arthritis and was evident in the mouse surgical model
of osteoarthritis (destabilization of the medial meniscus).
Conclusions: Together our data show that OSM, acting alone or in
synergy with IL-1 or together with TNF, is a potent regulator of IL-6
and RANKL expression in SFs. These effects of OSM are dependent
on OSMR expression. The ability of OSM and IL-1 to cross-regulate
expression of their respective receptors contributes to the synergistic
effect of these cytokines in SFs. This study identiﬁes a signiﬁcant role
for OSM, acting through OSMR, in mediating inﬂammation and bone
destruction in arthritic joints.
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SMART, THIN WOMEN WITH HIGHER VITAMIN D INTAKE AND
TALL MEN WITH A HAPPY CHILDHOOD ARE PROTECTED FROM
ULTRASOUND FEATURES OF HIP OSTEOARTHRITIS: THE NEWCASTLE
THOUSAND FAMILIES STUDY
A. Abraham1, M.S. Pearce1, K.D. Mann1, R.M. Francis2, F. Birrell3. 1Inst. of
Hlth.and Society, Newcastle Univ., Newcastle upon Tyne, United Kingdom;
2Inst. for Ageing and Hlth., Newcastle Univ., Newcastle upon Tyne, United
Kingdom; 3Musculoskeletal Res. Group, Inst. of Cellular Med., Newcastle
Univ., Newcastle upon Tyne, United Kingdom
Purpose: There has been a paucity of lifecourse research on the risk
of osteoarthritis (OA). We performed a lifecourse analysis of potential
risk factors for hip OA (deﬁned by osteophytes and femoral head score
on ultrasound) acting at different stages of life, among members of the
Newcastle Thousand Families birth cohort.
Methods: Potential risk factors for hip OA (including birth weight and
breast feeding data) have been collected prospectively in this birth cohort
and an a priori conceptual framework was developed. Participants from
the cohort aged 63 years (born in May-June 1947), had both hips scanned
by a trained musculoskeletal sonographer. Ultrasound protocols were
derived from EULAR guidelines. Hip OA was considered to be present if
an osteophyte or femoral head abnormality was identiﬁed. These data
were analysed in relation to a range of factors from across the lifecourse
using logistic regression models.
Results: Prevalence of hip OA was 26%, 30% and 40% for right, left
and “any” hip, respectively; among 311 participants. There was no
signiﬁcant difference of hip OA prevalence between males and females
(p = 0.8). While birth weight, exclusive breast feeding at birth, adverse
life events in childhood and height at age 50 showed signiﬁcant
univariate associations with hip OA in men, it was only adverse life
events in childhood (OR 3.56 one event vs no event; 95% CI 1.16, 10.9;
p = 0.03) and height at age 50 (OR 0.87 per cm; CI 0.79, 0.96; p = 0.004)
that showed signiﬁcant associations in the adjusted model for males.
Exclusive breast feeding (OR 0.77 per month; CI 0.58, 1.01; p = 0.06)
showed borderline signiﬁcance in the adjusted model for males. In
contrast, higher education level (OR 0.10 graduate vs not completed
school; CI 0.01, 0.85; p = 0.03) and dietary intake of vitamin D at age 50
(OR 0.75 per microgram per day; CI 0.59, 0.95; p = 0.02) were found to
be protective against hip OA in women, while an increased body fat
percentage at age 50 conferred a slightly higher risk of hip OA (OR 1.05;
CI 1.0, 1.1; p = 0.03) in the adjusted model for women.
Conclusions: This is the ﬁrst study to perform a lifecourse analysis of hip
OA risk using prospectively collected data. Tall men with no adverse life
events in childhood were at a signiﬁcantly decreased risk of hip OA in
this study. Increased height might be a function of genetic status, better
nutrition (at birth and in childhood), decreased infections and/or better
socio-economic status; the factors for the association of hip OA with
height require further study to explain this relationship. Adverse life
events in childhood might inﬂuence their effect on subsequent hip OA
through psychological and social pathways, which was beyond the scope
of this study. The borderline signiﬁcance of exclusive breast feeding in
men is an interesting ﬁnding. While breast feeding is known to decrease
risk of adult obesity and therefore of hip OA, this study suggests that
exclusive breast feeding might be an independent predictor of hip OA in
men. The mechanism for this could be reduced burden of infection and
inﬂammation through the lifecourse – a testable hypothesis.
The protective effect of higher education in women from subsequent hip
OA is a novel ﬁnding. We hypothesise that this might reﬂect adoption of
healthier lifestyles among educated women or might even be a function
of their improved utilisation and uptake of healthcare services. The
protective effect of dietary intake of vitamin D in women is in line with
results from the Study of Osteoporotic fractures (NE Lane et al, Arthritis
Rheum; 1999)which showed a similar protective effect of dietary Vitamin
D intake on incident hip OA in women. This protective effect of vitamin
D intake was independent of its effect on BMD at age 50. The ﬁndings of
this study have potential implications to public health policy especially
with regard to dietary vitamin D intake in women.
